| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7630643 | Journal of Pharmaceutical and Biomedical Analysis | 2015 | 9 Pages |
Abstract
- Bispecificity of therapeutic anti-Ang2/VEGF-CrossMab allows for specific depletion.
- Immunodepletion eliminates anti-Ang2/VEGF-CrossMab along with drug-bound Ang2.
- Drug capturing uses an anti-idiotypic antibody specific for the VEGF binding site.
- Free Ang2 determination uses immunodepletion prior to established Ang2 measurement.
- Reduced free Ang2 levels in patient samples confirm the mode of action of the drug.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Kay Stubenrauch, Uwe Wessels, Ulrich Essig, Rudolf Vogel, Harald Waltenberger, Andre Hansbauer, Astrid Koehler, Julia Heinrich,